Nlrp3 Inflammasome - Toxicology

Relevant Publications

Interaction Between Autophagy and the Inflammasome in Human Tumors: Implications for the Treatment of Human Cancers.

Issue Release: 2025

Prenatal Methamphetamine Exposure Impairs Helping Behaviour in Male Offspring: The Possible Role of miR-223 and NLRP3 Inflammasomes in the Amygdala.

Issue Release: 2025

The IRE1-XBP1 Axis Regulates NLRP3 Inflammasome-Mediated Microglia Activation in Hypoxic Ischemic Encephalopathy.

Issue Release: 2025

NLRP3 Inflammasome Activation and Altered Mitophagy Are Key Pathways in Inclusion Body Myositis.

Issue Release: 2025

Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway.

Issue Release: 2024

Activation of TAS2R4 signaling attenuates podocyte injury induced by high glucose.

Issue Release: 2024

NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.

Issue Release: 2024

Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development.

Issue Release: 2024

Estrogen receptor β activation alleviates inflammatory bowel disease by suppressing NLRP3-dependent IL-1β production in macrophages via downregulation of intracellular calcium level.

Issue Release: 2024

Homotherapy for heteropathy: therapeutic effect of Butein in NLRP3-driven diseases.

Issue Release: 2024

Vaccarin alleviates septic cardiomyopathy by potentiating NLRP3 palmitoylation and inactivation.

Issue Release: 2024

Iguratimod Alleviates Experimental Sjögren\'s Syndrome by Inhibiting NLRP3 Inflammasome Activation.

Issue Release: 2024

Astragaloside IV ameliorates indomethacin-induced intestinal inflammation in rats through inhibiting the activation of NLRP3 inflammasome.

Issue Release: 2024

Intestinal GSTpi deficiency exacerbates the severity of experimental hyperlipidemic acute pancreatitis.

Issue Release: 2024

Tryptanthrin suppresses multiple inflammasome activation to regulate NASH progression by targeting ASC protein.

Issue Release: 2024

Anti-rheumatic property and physiological safety of KMU-11342 in in vitro and in vivo models.

Issue Release: 2024

P2X7 receptor deficiency attenuates cisplatin-induced kidney injury via inhibiting NLRP3 inflammasome activation.

Issue Release: 2024

Epigallocatechin-3-gallate Inhibits LPS/AβO-induced Neuroinflammation in BV2 Cells through Regulating the ROS/TXNIP/NLRP3 Pathway.

Issue Release: 2024

Hecogenin alleviates LPS-induced osteolysis via regulating pyroptosis and ROS involved Nrf2 activation.

Issue Release: 2024

Novel NLRP3 inhibitor INF195: Low doses provide effective protection against myocardial ischemia/reperfusion injury.

Issue Release: 2024

What are Common Toxins that Alter Immune Regulation?

How is Ureteroscopy Performed?

What are the Future Directions in Adenovirus Research?

Can Lifestyle Choices Mitigate Weight Gain from Toxicants?

Why is Risk Prediction Important?

What is Particle Induced Toxicity?

What is Polyester?

What Causes Immediate Hypersensitivity?

Can Ribosomal Damage Be Reversed?

What is the Impact of Biosimilars on Healthcare?

Partnered Content Networks

Relevant Topics